Extracorporal low-density lipoprotein elimination by immunoadsorption.
Low-density lipoprotein (LDL) apheresis has proven its therapeutic usefulness in patients who suffer from coronary heart disease but cannot achieve LDL cholesterol concentrations defined by the National Cholesterol Education Program guidelines. Immunoadsorption was the first commercially available apheresis technique. It is based on affinity chromatography. As with other apheresis techniques, immunoadsorption has specific advantages and disadvantages. These have to be taken into account when selecting an apheresis technique for the individual patient.
Ritter
M M
MM
Medizinische Klinik, Klinikum Ibbenbüren, Ibbenbüren, Germany. M.Ritter@Krankenhaus-Ibbenbueren.de
Parhofer
K G
KG
D001781:Blood Component Removal / Q000379:methods; D008078:Cholesterol, LDL / Q000097:blood*; D003324:Coronary Artery Disease / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000628:therapy*; D007163:Immunosorbent Techniques; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification*; D008297:Male; D010956:Plasmapheresis / Q000379:methods*; D018570:Risk Assessment; D016896:Treatment Outcome
D008078:Cholesterol, LDL; D008077:Lipoproteins, LDL